Point of Care test development for Chlamydia

Project: Research project

Project Details


The Center for Innovation in Global Health Technologies (CIGHT) is collaborating with the Quidel Corporation to develop Savanna, an integrated molecular platform and nucleic acid based tests for infectious diseases to be marketed in limited resource settings. Biohelix, a subsidiary of the Quidel Corporation, has developed a helicase dependent amplification assay that detects 50 copies of Chlamydia trachomatis (CT) from purified DNA in 20 minutes. We propose to develop sample prep method that will allow us to port this assay on the Savanna molecular platform to perform fully-automated DNA extraction & amplification from swab or urine specimens in less than 30 minutes.
Effective start/end date4/1/159/30/15


  • Johns Hopkins University Applied Physics Laboratory (126644// 2U54EB007958-06)
  • National Institute of Biomedical Imaging and Bioengineering (126644// 2U54EB007958-06)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.